President, Inventor, and Founder
Founded SignaBlok in 2009 after previously founding the AMW Biomed Company and working at Massachusetts Institute of Technology, where discovered the homooligomerization of intrinsically disordered proteins. The sole inventor of methods and compositions created through the SCHOOL platform of receptor inhibition that can be used to prevent or treat multiple series diseases with unmet needs. Developed integrated nanosystems for targeted delivery of therapeutics and imaging agents to macrophage-rich sites of disease in vivo. PhD in Chemistry from Moscow State University, Russia.